Revvity, Inc. (NYSE:RVTY) Shares Sold by Bay Colony Advisory Group Inc d b a Bay Colony Advisors

Bay Colony Advisory Group Inc d b a Bay Colony Advisors cut its holdings in Revvity, Inc. (NYSE:RVTY - Free Report) by 56.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,332 shares of the company's stock after selling 4,364 shares during the quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors' holdings in Revvity were worth $372,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in RVTY. Janus Henderson Group PLC increased its position in Revvity by 1.7% in the 3rd quarter. Janus Henderson Group PLC now owns 6,335,302 shares of the company's stock valued at $809,332,000 after buying an additional 108,401 shares in the last quarter. State Street Corp raised its holdings in Revvity by 0.3% during the 3rd quarter. State Street Corp now owns 5,180,169 shares of the company's stock valued at $661,767,000 after acquiring an additional 17,832 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Revvity by 0.9% in the third quarter. Geode Capital Management LLC now owns 2,863,793 shares of the company's stock worth $364,569,000 after buying an additional 25,078 shares in the last quarter. EdgePoint Investment Group Inc. increased its stake in Revvity by 34.6% in the 3rd quarter. EdgePoint Investment Group Inc. now owns 2,685,775 shares of the company's stock worth $343,108,000 after acquiring an additional 690,534 shares during the last quarter. Finally, RGM Capital LLC raised its position in shares of Revvity by 3.2% during the 3rd quarter. RGM Capital LLC now owns 980,858 shares of the company's stock valued at $125,305,000 after buying an additional 30,000 shares in the last quarter. Institutional investors own 86.65% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on RVTY. Bank of America upgraded Revvity from a "neutral" rating to a "buy" rating and set a $138.00 target price for the company in a report on Friday, December 13th. Sanford C. Bernstein lowered shares of Revvity from an "outperform" rating to a "market perform" rating and set a $130.00 price objective for the company. in a report on Friday, January 10th. Raymond James reiterated an "outperform" rating and issued a $145.00 price target (up from $140.00) on shares of Revvity in a research note on Monday, February 3rd. Barclays upped their price target on Revvity from $135.00 to $140.00 and gave the stock an "overweight" rating in a research note on Monday, February 3rd. Finally, KeyCorp increased their price objective on shares of Revvity from $132.00 to $145.00 and gave the company an "overweight" rating in a research report on Monday, February 3rd. Four analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $136.25.

Insider Activity

In related news, insider Joel S. Goldberg sold 15,170 shares of the stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $126.73, for a total value of $1,922,494.10. Following the completion of the sale, the insider now directly owns 33,400 shares in the company, valued at approximately $4,232,782. This represents a 31.23 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Tajinder S. Vohra sold 5,492 shares of Revvity stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $116.81, for a total transaction of $641,520.52. Following the sale, the insider now owns 19,652 shares in the company, valued at $2,295,550.12. This represents a 21.84 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.60% of the company's stock.

Revvity Stock Performance

Shares of Revvity stock traded down $1.20 during midday trading on Wednesday, hitting $111.73. The company had a trading volume of 978,943 shares, compared to its average volume of 951,364. Revvity, Inc. has a 12-month low of $97.32 and a 12-month high of $129.50. The company has a fifty day simple moving average of $117.07 and a 200 day simple moving average of $118.14. The company has a quick ratio of 3.03, a current ratio of 3.60 and a debt-to-equity ratio of 0.41. The stock has a market cap of $13.42 billion, a price-to-earnings ratio of 50.55, a PEG ratio of 3.82 and a beta of 1.06.

Revvity (NYSE:RVTY - Get Free Report) last posted its quarterly earnings data on Friday, January 31st. The company reported $1.42 EPS for the quarter, topping the consensus estimate of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same quarter last year, the company posted $1.25 earnings per share. As a group, analysts predict that Revvity, Inc. will post 4.94 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 9th. Stockholders of record on Friday, April 18th will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.25%. The ex-dividend date of this dividend is Thursday, April 17th. Revvity's dividend payout ratio is currently 12.67%.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.